Veligrotug

维古塔单抗

Report date: 2026/02/13 20:01:31

Base Information

Drug NameVeligrotug
Drug Alias NameVRDN-001ZB-001AVE-1642
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsSolid tumoursGraves OphthalmopathyBreast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandNetherlands +[10] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesViridian Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesDRI Healthcare TrustZai Lab LtdImmunogen Inc +[7] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursGraves OphthalmopathyBreast Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A